doi:10.3390/biom11020217 Bach LA, Hsieh S, Sakano K, Fujiwara H, Perdue JF, Rechler MM
Phase 1b/2a Subcutaneous Formulation (Obesity) Published: The Lancet, June 2025 Participants: 125 adults with overweight or obesity (BMI 27.039.9), aged 1855 Duration: Up to 36 weeks Dosing: Once-weekly subcutaneous amycretin, up to 60 mg Results: - Up to 22% absolute weight loss at 36 weeks (highest dose group) - Placebo-adjusted difference: approximately 24% - No weight-loss plateau observed at study end Safety: 81% of the 89 participants who reported a TEAE had gastrointestinal events
Platelets in inflammation: regulation of leukocyte activities and vascular repair
Biopharm Drug Dispos 24:357365 Israr MZ, Ibrahim W, Salzano A, Sarmad S, Wilde MJ, Cordell RL, Greening NJ, Brightling CE, Siddiqui S, Suzuki T, Consortium E (2022) Association of gut-related metabolites with respiratory symptoms in Covid-19: a proof-of-concept study